Amylyx Pharmaceuticals, Inc. · NASDAQ:AMLX
Amylyx Pharmaceuticals — ENDO (Endocrine Society)
6 slides from Amylyx Pharmaceuticals's conference presentation
Slide 1: Reduction in Rate of Hypoglycemic Events with Avexitide in Post-Bariatric Hypoglycemia
Reduction in Rate of Hypoglycemic Events with Avexitide in Post-Bariatric Hypoglycemia: Results from the Phase 2 and 2B Studies Marilyn Tan, MD Stanford University School of Medicine Additional Authors: Colleen Craig, MD; Tracey McLaughlin, MD, MS; Zhengyu Yang, PhD; Kelly Fox, MD; Ryan Miller, MD;
Slide 2: Post-Bariatric Hypoglycemia is a Chronic Condition with Recurrent, Debilitating Hypoglycemia
Post-Bariatric Hypoglycemia (PBH) is a Chronic Condition Characterized by Recurrent, Debilitating Hyperinsulinemic Hypoglycemia after Bariatric Surgery1 A Key Pathway in PBH Pathophysiology2 1 2 3 Altered Stomach Increased GLP-1 Secretion Hyper-Secretion of Insulin into the Bloodstream GLP-1 Islet G
Slide 3: Two Phase 2 Trials Evaluated Efficacy and Safety of Avexitide for PBH
Two Phase 2 Trials Have Been Conducted to Evaluate the Efficacy and Safety of Avexitide for the Treatment of PBH PHASE 2 PREVENT TRIAL DESIGN - 28-day, randomized, placebo-controlled crossover trial (N = 18*) 14-day Treatment Period 14-day Treatment Period 14-day Treatment Period Participants enroll
Slide 4: Avexitide Significantly Reduced Rates of Hypoglycemia by SMBG and eDiary
Avexitide Significantly Reduced Rates of Level 2 and 3 Hypoglycemia by SMBG and eDiary in Two Phase 2 Clinical Trials % Reduction in Ratea of Hypoglycemia with avexitide vs placebo (Ph 2) or Run-In (Ph 2b)b 100 Level 2 c Level 3 d 68% 66% 80 60% 56% 57% p=0.0003 p=0.0003 53% % Reduction p=0.004 p=0.
Slide 5: Avexitide Significantly Reduced Rates of Composite Hypoglycemia in Exploratory Analyses
Avexitide Significantly Reduced Rates of Composite Level 2 and 3 Hypoglycemia in New Exploratory Analyses from Two Phase 2 Clinical Trials % Reduction in Composite Ratea of Level 2b and 3c Hypoglycemia with avexitide vs placebo (Ph 2) or Run-In (Ph 2b)d Greater Rate 100 Reduction in Rate of Hypoglyc
Slide 6: Key Takeaways
Scan to Learn More about the LUCIDITY Trial Key Takeaways • Avexitide significantly reduced rates of composite Level 2 and 3 hypoglycemia in its Phase 2 and 2b trials – Adverse events were generally mild to moderate and transient with no treatment-related serious adverse events and no adverse events